p53 mutations and resistance to chemotherapy: A stab in the back for p73?;p53 mutantes et résistance à la chimiothérapie: Un coup dans le dos de p73 ?

Bulletin du Cancer

Volumn 90, Issue 5, 2003, Pages 383-386

  Soussi, Thierry ^a  

^a NONE

Author keywords

Chemotherapy; p53

Indexed keywords

CYTOTOXIC AGENT; PROTEIN P53; PROTEIN P63; PROTEIN P73; DNA BINDING PROTEIN; NUCLEAR PROTEIN; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

APOPTOSIS; CANCER; CANCER CHEMOTHERAPY; DNA DAMAGE; GENE INACTIVATION; GENE MUTATION; GENETIC TRANSCRIPTION; MALIGNANT TRANSFORMATION; MULTIGENE FAMILY; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; CELL TRANSFORMATION; DRUG RESISTANCE; GENETICS; HUMAN; MUTATION; NEOPLASM; TUMOR SUPPRESSOR GENE;

APOPTOSIS; CELL TRANSFORMATION, NEOPLASTIC; DNA DAMAGE; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; GENES, P53; GENES, TUMOR SUPPRESSOR; HUMANS; MUTATION; NEOPLASMS; NUCLEAR PROTEINS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 0042205846     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 2003; 3: 387-402.
2. Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, Kaelin WJ. Chemosensitivity linked to p73 function. Cancer Cell 2003; 3: 403-10.
3. Soussi T. p53 mutations and resistance to chemotherapy: a stab in the back for p73. Cancer Cell 2003; 3: 303-5.
4. Eliyahu D, Michalovitz D, Eliyahu S, Pinhasikimhi O, Oren M. p53-oncogene or anti-oncogene? Oncogenes Cancer Diag 1990; 39: 125-34.
5. Lane DP, Benchimol S. p53: oncogene or anti-oncogene? Genes Develop 1990; 4: 1-8.
6. Soussi T, Béroud C. Assessing Tp53 status in human tumours to evaluate clinical outcome. Nature Rev Cancer 2001; 1: 233-40.
7. Cho YJ, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor DNA complex: understanding tumorigenic mutations. Science 1994; 265: 346-55.
8. Ory K, Legros Y, Auguin C, Soussi T. Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J 1994 13: 3496-504.
9. Forrester K, Lupold SE, Ort VL, Chay CH, Band V, Wang XW, Harris CC. Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. Oncogene 1995; 10: 2103-11.
10. Dirtmer D, Pari S, Zambetri G, Chu S, Teresky AK, Moore M, et al. Gain of function mutations in p53. Nature Genetics 1993; 4: 42-6.
11. Halevy O, Michalovitz D, Oren M. Different tumor-derived p53 mutants exhibit distinct biological activities. Science 1990; 250: 113-6.
12. Aas T, Borresen AL, Geisler S, Smithsorensen B, Johnsen H, Varhaug JE, et al. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Med 1996; 2: 811-4.
13. Jacquemin-Sablon A. Mutations du gène p53: avantage ou inconvénient pour la chimiothérapie ? Bull Cancer 1997; 84: 741-6.
14. Blandino G, Levine AJ, Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 1999; 18: 477-85.
15. Melino G, De Laurenzi V, Vousden KH. p73: Friend or foe in tumorigenesis. Nat Rev Cancer 2002; 2: 605-15.
16. Benard J, Ahomadegbe JC. Statut tumoral de p53 et réponse à la chimiothérapie. Bull Cancer 2002; 89: 1007-10.
17. DiComo CJ, Gaiddon C, Prives C. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol Cell Biol 1999; 19: 1438-49.
18. Strano S, Fontemaggi G, Costanzo A, Rizzo MG, Monti O, Baccarini A, et al. Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem 2002; 272: 188817-26.
19. Marin MC, Josr CA, Brooks LA, Irwin MS, O'Nions J, Tidy JA, et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nature Genet 2000; 25: 47-54.
20. Bensaad K, Le Bras M, Unsal K, Strano S, Blandino G, Tominaga O, et al. Change of conformation of the DNA binding domain of p53 is the only key element for binding of and interference with p73. J Biol Chem 2003 (in press).
21. Beckman G, Birgander R, Sjalander A, Saha N, Holmberg PA, Kivela A. Is p53 polymorphism maintained by natural selection? Hum Hered 1994; 44: 266-70.
22. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998; 393: 229-34.
23. Helland A, Langerod A, Johnsen H, Olsen AO, Skovlund E, Borresen-Dale AL. p53 polymorphism and risk of cervical cancer. Nature 1998; 396: 530-1.
24. Hildesheim A, Schiffman M, Brinton LA, Fraumeni JF, Herrero R, Btatti MC, et al. p53 polymorphism and risk of cervical cancer. Nature 1998; 396: 531-2.
25. Josefsson AM, Magnusson PKE, Ylitalo N, Quarforrh Tubbin P, Ponten J, Adami HO, et al. p53 polymorphism and risk of cervical cancer. Nature 1998; 396: 531.
26. Lanham S, Campbell I, Watt P, Gornall R. p53 polymorphism and risk of cervical cancer. Lancet 1998; 352: 1631-1.
27. Soussi T, Beroud C. Significance of Tp53 mutations in human cancer: a critical analysis of mutations at CpG dinucleotides. Hum Mutat 2003; 21: 192-200.
28. Jeanteur P. Peut on guérir la p53 ? Bull Cancer 2000; 87: 131-2.
29. Martinez LA, Naguibneva I, Lehrmann H, Vervisch A, Tchenio T, Lozano G, et al. Synthetic small inhibiting RNAs: efficient rools to inactivate oncogenic mutations and restore p53 pathways. Proc Natl Acad Sci USA 2002; 99: 14849-54.